:Losartan    (DrugBank: Losartan)

18 diseases
告示番号疾患名(ページ内リンク)臨床試験数
17多系統萎縮症1
19ライソゾーム病2
36表皮水疱症2
46悪性関節リウマチ1
58肥大型心筋症4
66IgA腎症7
67多発性嚢胞腎1
85特発性間質性肺炎2
96クローン病1
97潰瘍性大腸炎1
98好酸球性消化管疾患2
113筋ジストロフィー1
164眼皮膚白皮症1
167マルファン症候群12
179ウィリアムズ症候群1
215ファロー四徴症2
222一次性ネフローゼ症候群3
299嚢胞性線維症2

17. 多系統萎縮症 [臨床試験数:107,薬物数:153(DrugBank:48),標的遺伝子数:59,標的パスウェイ数:104
Searched query = "Multiple system atrophy", "MSA-C", "MSA-P", "Olivopontocerebellar atrophy", "OPCA", "Striatonigral degeneration", "Shy-Drager syndrome"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
1 / 107 trial found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT01292694March 20118/2/2011Contribution of Angiotensin II to Supine Hypertension in Autonomic FailureContribution of Angiotensin II to Supine Hypertension in Autonomic FailureHypertension;Pure Autonomic Failure;Multiple System AtrophyDrug: Losartan;Drug: Captopril;Drug: PlaceboVanderbilt UniversityNULLTerminated18 Years85 YearsAll12Phase 1United States

19. ライソゾーム病 [臨床試験数:784,薬物数:673(DrugBank:101),標的遺伝子数:68,標的パスウェイ数:184
Searched query = "Lysosomal storage disease", "Lysosomal disease", "Gaucher disease", "Niemann-Pick disease", "Niemann-Pick type C", "GM1-gangliosidosis", "GM1-gangliosidoses", "GM2-gangliosidosis", "GM2-gangliosidoses", "Tay-Sachs disease", "Sandhoff disease", "Krabbe disease", "Metachromatic leukodystrophy", "Multiple-sulfatase deficiency", "Farber disease", "Mucopolysaccharidosis type I", "Mucopolysaccharidosis I", "MPS I", "Hurler syndrome", "Scheie syndrome", "Mucopolysaccharidosis type II", "Mucopolysaccharidosis II", "MPS II", "Hunter syndrome", "Mucopolysaccharidosis type III", "Mucopolysaccharidosis III", "MPS III", "Sanfilippo syndrome", "Mucopolysaccharidosis type IV", "Mucopolysaccharidosis IV", "MPS IV", "MPS IVA", "Morquio syndrome", "Morquio A syndrome", "Mucopolysaccharidosis type VI", "Mucopolysaccharidosis VI", "MPS VI", "Maroteaux-Lamy syndrome", "Mucopolysaccharidosis type VII", "Mucopolysaccharidosis VII", "MPS VII", "Sly syndrome", "Mucopolysaccharidosis type IX", "Mucopolysaccharidosis IX", "MPS IX", "Hyaluronidase deficiency", "Sialidosis", "Galactosialidosis", "Mucolipidosis II", "Mucolipidosis type II", "I-cell disease", "Mucolipidosis III", "Mucolipidosis type III", "Alpha-Mannosidosis", "Alpha-Mannosidase Deficiency", "Beta-Mannosidosis", "Beta-Mannosidase Deficiency", "Fucosidosis", "Aspartylglucosaminuria", "Schindler disease", "Kanzaki disease", "Pompe disease", "Acid lipase deficiency", "Wolman disease", "Cholesterol ester storage disease", "Danon disease", "Free sialic acid storage disease", "Salla disease", "Ceroid lipofuscinosis", "Fabry disease", "Cystinosis"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
2 / 784 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT03632213November 7, 20183/8/2018Evaluation of Losartan on Cardiovascular Disease in Patients With Mucopolysaccharidoses IV A and VIA Randomized Clinical Trial to Evaluate the Effects of Losartan on Cardiovascular Disease in Patients With Mucopolysaccharidoses IV A and VIMucopolysaccharidosis IV A;Mucopolysaccharidosis VI;Mucopolysaccharidoses;MPS IV A;MPS VI;MPS - Mucopolysaccharidosis;Morquio A Syndrome;Morquio Syndrome A;Morquio SyndromeDrug: Losartan;Drug: PlaceboHospital de Clinicas de Porto AlegreThe Isaac FoundationRecruiting10 Years40 YearsAll30Phase 2Brazil
2NCT00446862March 200711/3/2007The Fabrazyme® and Arbs and ACE Inhibitor Treatment (FAACET) StudyMulti-center, Open-label Study of the Safety and Efficacy of Control of Proteinuria With ACE Inhibitors and ARBS in Patients With Fabry Disease Who Are Receiving Fabrazyme®: The FAACET StudyFabry Disease;ProteinuriaDrug: enalapril and other angiotensin converting enzyme inhibitors; losartan and other angiotensin receptor blockersUniversity of Alabama at BirminghamNULLCompleted19 Years85 YearsBoth36N/AUnited States;Slovenia;Germany

36. 表皮水疱症 [臨床試験数:147,薬物数:170(DrugBank:40),標的遺伝子数:32,標的パスウェイ数:113
Searched query = "Epidermolysis bullosa", "EBS", "JEB", "DDEB", "RDEB", "Kindler syndrome"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
2 / 147 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2015-003670-32-AT05/10/201707/08/2017Phase I/II trial to establish safety, tolerability and efficacy of losartan in children with epidermolysis bullosaA dual-center prospective phase I/II trial to establish safety, tolerability and to obtain first data on efficacy of losartan in children with recessive dystrophic epidermolysis bullosa (RDEB) - REFLECT Recessive dystrophic epidermolysis bullosa (RDEB)
MedDRA version: 20.0Level: PTClassification code 10014989Term: Epidermolysis bullosaSystem Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Skin and Connective Tissue Diseases [C17]
Trade Name: Losartan HEXAL
INN or Proposed INN: losartan potassium
Other descriptive name: LOSARTAN POTASSIUM
Medical Center - University of FreiburgNULLNot RecruitingFemale: yes
Male: yes
30Phase 2Austria;Germany
2EUCTR2015-003670-32-DE07/04/2016Phase I/II trial to establish safety, tolerability and efficacy of losartan in children with epidermolysis bullosaA dual-center prospective phase I/II trial to establish safety, tolerability and to obtain first data on efficacy of losartan in children with recessive dystrophic epidermolysis bullosa (RDEB) - REFLECT Recessive dystrophic epidermolysis bullosa (RDEB)
MedDRA version: 20.0Level: PTClassification code 10014989Term: Epidermolysis bullosaSystem Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Skin and Connective Tissue Diseases [C17]
Trade Name: Losartan HEXAL
INN or Proposed INN: losartan potassium
Other descriptive name: LOSARTAN POTASSIUM
Medical Center - University of FreiburgNULLNAFemale: yes
Male: yes
30Phase 2Austria;Germany

46. 悪性関節リウマチ [臨床試験数:4,183,薬物数:2,538(DrugBank:401),標的遺伝子数:183,標的パスウェイ数:219
Searched query = "Malignant rheumatoid arthritis", "Rheumatoid arthritis", "Rheumatoid arthritis with vasculitis"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
1 / 4,183 trial found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT02246257September 201417/9/2014Early Rheumatoid Arthritis COR InterventionMultifactorial Intervention to Prevent Cardiovascular Disease in Patients With Early Rheumatoid ArthritisRheumatoid Arthritis;Cardiovascular DiseasesOther: Simvastatin;Other: Losartan;Other: Metformin;Other: Outpatient rheumatology department;Other: Refered to general practiceMD, PhD, Annemarie Lyng SvenssonNULLUnknown status18 YearsN/AAll300N/ADenmark

58. 肥大型心筋症 [臨床試験数:92,薬物数:126(DrugBank:35),標的遺伝子数:40,標的パスウェイ数:141
Searched query = "Hypertrophic cardiomyopathy"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
4 / 92 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT01447654November 20114/10/2011Inhibition of the Renin Angiotensin System With Losartan in Patients With Hypertrophic CardiomyopathyINHibition of the Renin Angiotensin System in Hypertrophic Cardiomyopathy and the Effect on Ventricular Hypertrophy - a Randomized Intervention Trial With Losartan.Hypertrophic CardiomyopathyDrug: Losartan;Drug: PlaceboHenning BundgaardNULLCompleted18 YearsN/ABoth130Phase 2Denmark
2EUCTR2011-001191-19-DK26/10/201112/09/2011Effects on the heart in patients with hypertophic cardiomyopathy when treated with losartan.Cardiac effects of inhibition of the renin angiotensin system with losartan in patients with hypertrophic cardiomyopathy. Hypertrophic cardiomyopathy
MedDRA version: 14.0Level: LLTClassification code 10020876Term: Hypertrophic obstructive cardiomyopathySystem Organ Class: 10007541 - Cardiac disorders;Therapeutic area: Diseases [C] - Cardiovascular Diseases [C14]
Trade Name: Losartan Bluefish 50 mg
Product Name: Losartan
Hjertemedicinsk klinik B, 2142, RigshospitaletNULLNot RecruitingFemale: yes
Male: yes
Denmark
3NCT01150461February 200722/6/2010Effect of Losartan in Patients With Nonobstructive Hypertrophic CardiomyopathyEffect of Losartan in Patients With Nonobstructive Hypertrophic CardiomyopathyHypertrophic CardiomyopathyDrug: losartan;Drug: placeboMassachusetts General HospitalNULLCompleted18 YearsN/AAll20Phase 2United States
4NCT00001534September 19963/11/1999Long Term Effects of Enalapril and Losartan on Genetic Heart DiseaseDouble-Blind, Placebo-Controlled Study of the Long Term Effects of Angiotensin Converting Enzyme Inhibition (Enalapril) and Angiotensin II Receptor Blockade (Losartan) on Genetically-Induced Left Ventricular Hypertrophy in Non-Obstructive HCMHypertrophic Cardiomyopathy;Left Ventricular Hypertrophy;Myocardial IschemiaDrug: LosartanNational Heart, Lung, and Blood Institute (NHLBI)NULLCompletedN/AN/ABoth112N/AUnited States

66. IgA腎症 [臨床試験数:199,薬物数:214(DrugBank:57),標的遺伝子数:32,標的パスウェイ数:128
Searched query = "IgA nephropathy", "IgA nephritis", "Berger disease", "IgA-IgG nephropathy"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
7 / 199 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1ChiCTR-IIR-170134872018-01-012017-11-22A multicenter, double blind, double dummy, randomized controlled clinical study on the treatment of IgA nephropathy with Zhengqingfengtongning extantabA multicenter, double blind, double dummy, randomized controlled clinical study on the treatment of IgA nephropathy with Zhengqingfengtongning extantab IgA nephropathyExperimental group:Zhengqing Fengtongning extantab;Control group 1:Losartan Potassium Tablets;Control group 2:Losartan Potassium Tablets + Zhengqing Fengtongning extantab;The Third Xiangya Hospital of Central South UniversityNULLRecruiting1870BothExperimental group:36;Control group 1:36;Control group 2:36;4 (Phase 4 study)China
2NCT02231125September 201430/8/2014Efficacy and Safety of Abelmoschus Manihot for IgA NephropathyEfficacy and Safety of Abelmoschus Manihot for IgA Nephropathy: a Multicentre, Double-blind, Double-dummy, Randomized Controlled TrialIgA NephropathyDrug: Losartan;Drug: Abelmoschus manihotChen XiangmeiJiangsu Suzhong Pharmaceutical Group Co., Ltd.Recruiting18 Years65 YearsBoth1600Phase 4China
3NCT01854814July 20139/5/2013The Effects of Mycophenolate Mofetil (MMF) on Renal Outcomes in Advanced Immunoglobulin A (IgA) Nephropathy PatientsThe Effects of Mycophenolate Mofetil on Renal Outcomes in Patients With Advanced IgA Nephropathy: a Randomized Open-label StudyIgA NephropathyDrug: Mycophenolate mofetil;Drug: LosartanFan Fan HouNULLRecruiting16 Years70 YearsAll232N/AChina
4JPRN-UMIN0000028872009/12/0114/12/2009A multicenter study to examine renal protection by a combination of an HMG-CoA reductase inhibitor and losartan in patients with dyslipidemia associated with IgA nephropathy IgA nephropathystatin and losartan group:
simvastatin 5mg and Losartan 50mg/day more than 3 months
statin group:
simvastatin 5mg/day more than 3 months
Fukuoka University Faculty of MedicineNULLRecruiting20years-oldNot applicableMale and Female80Not selectedJapan
5NCT00922311July 200914/6/2009Aliskiren for Proteinuric IgAN Despite Angiotensin BlockadeAliskiren Combined With Losartan in Immunoglobulin A Nephropathy: an Open-label Pilot StudyIgA NephropathyDrug: AliskirenThe University of Hong KongQueen Mary Hospital, Hong Kong;United Christian HospitalCompleted18 Years70 YearsBoth25Phase 4China
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
6ChiCTR-TRC-060000042006-01-012006-09-14ACEi/ARB alone versus ACEi/ARB plus Steroids in the treatment of primary IgA nephropathy, a randomized multicenter controlled trialACEi/ARB alone versus ACEi/ARB plus Steroids in the treatment of primary IgA nephropathy, a randomized multicenter controlled trial primary IgA nephropathygroup 1:treated with ACEI/ARB( ARB therapy is subjected to patients with cough after use of ACEI) Inhibace (cilazapril): start at 1.25mg/day, increase the dose by 1.25mg/day/week to 2.5-5mg/day Cozaar (losartan): 25~50mg/day, increased to 50~100mg/day Last for one year;group 2:Oral prednisone for 6 mos 0.8mg/kg/day x 8 wks Tapered 0.2mg/kg/day/mo in combination with ACEI/ARB;The First Hospital, Peking UniversityNULLCompleted1665Bothgroup 1:78;group 2:78;China
7JPRN-C0000000062005/01/0101/08/2005Lisinopril only and a combination of lisinopril and losartan for IgA nephropathy with focal mesangial proliferation in children: A randomized controlled trial of efficacy and safety IgA nephropathy in childrenLisinopril for 2 years
Lisinopril+losartan for 2 years
Japanese Study group of Kidney Disease in ChildrenNULLComplete: follow-up complete2years-old18years-oldMale and Female110Not selectedJapan

67. 多発性嚢胞腎 [臨床試験数:186,薬物数:196(DrugBank:47),標的遺伝子数:35,標的パスウェイ数:146
Searched query = "Polycystic kidney disease", "PKD", "PCKD", "Polycystic kidney", "ADPKD", "ARPKD"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
1 / 186 trial found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1ChiCTR-TRC-110012822011-04-012011-04-21Triptolide Retards Autosomal Dominant Polycystic Kidney Disease with ProteinuriaTriptolide Retards Autosomal Dominant Polycystic Kidney Disease with Proteinuria Autosomal dominant polycystic kidney disease;Q61.301Group A:Glucosidorum Tripterygll Totorum+losartan potassium ;Group B:Placebo + losartan potassium;Shanghai Changzheng HospitalNULLCompleted1855BothGroup A:30;Group B:30;China

85. 特発性間質性肺炎 [臨床試験数:514,薬物数:377(DrugBank:108),標的遺伝子数:97,標的パスウェイ数:204
Searched query = "Idiopathic interstitial pneumonia", "IIPs", "Idiopathic pulmonary fibrosis", "IPF", "Usual interstitial pneumonia", "UIP", "Non-specific interstitial pneumonia", "NSIP", "Acute interstitial pneumonia", "AIP", "Diffuse alveolar damage", "DAD", "COP", "Organizing pneumonia", "OP", "Desquamative interstitial pneumonia", "DIP", "Respiratory bronchiolitis - associated interstitial lung disease", "RB-ILD", "Lymphocytic interstitial pneumonia", "LIP"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
2 / 514 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT00981747September 200919/9/2009Targeting Vascular Reactivity in Idiopathic Pulmonary FibrosisA Clinical Treatment Trial Targeting Vascular Reactivity in Idiopathic Pulmonary FibrosisIdiopathic Pulmonary Fibrosis;Pulmonary FibrosisDrug: Sildenafil;Drug: Losartan;Drug: Sildenafil and Losartan;Drug: Placebo Oral TabletAlicia GerkePulmonary Fibrosis FoundationTerminated18 Years99 YearsAll12Phase 2/Phase 3United States
2NCT00879879March 200910/4/2009Losartan in Treating Patients With Idiopathic Pulmonary FibrosisTreatment of Idiopathic Pulmonary Fibrosis With Losartan: A Pilot ProjectPrecancerous ConditionDrug: losartanUniversity of South FloridaNational Cancer Institute (NCI)Completed21 YearsN/AAll20N/AUnited States

96. クローン病 [臨床試験数:2,209,薬物数:1,276(DrugBank:240),標的遺伝子数:166,標的パスウェイ数:210
Searched query = "Crohn disease", "Terminal ileitis"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
1 / 2,209 trial found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT02760615November 1, 20162/5/2016Phase 4, Vedolizumab-4002 Post-marketing, Disease-Drug-Drug Interaction StudyAn Open-Label, 2-Part, Multicenter, Post-marketing Study to Evaluate the Effect of Moderately or Severely Active Ulcerative Colitis or Crohn's Disease on Cytochrome P-450 Enzyme Substrates Compared to Healthy Subjects and the Effect of Vedolizumab Treatment on Cytochrome P-450 Enzyme Substrates in Subjects With Ulcerative Colitis or Crohn's DiseaseColitis, Ulcerative;Crohn DiseaseDrug: Caffeine;Drug: Losartan;Drug: Omeprazole;Drug: Dextromethorphan;Drug: Midazolam;Drug: VedolizumabTakedaNULLWithdrawn18 Years55 YearsAll0Phase 4United States

97. 潰瘍性大腸炎 [臨床試験数:2,269,薬物数:1,331(DrugBank:241),標的遺伝子数:114,標的パスウェイ数:181
Searched query = "Ulcerative colitis"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
1 / 2,269 trial found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT02760615November 1, 20162/5/2016Phase 4, Vedolizumab-4002 Post-marketing, Disease-Drug-Drug Interaction StudyAn Open-Label, 2-Part, Multicenter, Post-marketing Study to Evaluate the Effect of Moderately or Severely Active Ulcerative Colitis or Crohn's Disease on Cytochrome P-450 Enzyme Substrates Compared to Healthy Subjects and the Effect of Vedolizumab Treatment on Cytochrome P-450 Enzyme Substrates in Subjects With Ulcerative Colitis or Crohn's DiseaseColitis, Ulcerative;Crohn DiseaseDrug: Caffeine;Drug: Losartan;Drug: Omeprazole;Drug: Dextromethorphan;Drug: Midazolam;Drug: VedolizumabTakedaNULLWithdrawn18 Years55 YearsAll0Phase 4United States

98. 好酸球性消化管疾患 [臨床試験数:128,薬物数:147(DrugBank:40),標的遺伝子数:34,標的パスウェイ数:132
Searched query = "Eosinophilic gastrointestinal disease", "Eosinophilic gastroenteritis", "Eosinophilic esophagitis", "Eosinophilic colitis", "Eosinophilic gastro-intestinal disorder", "EGID", "Neonatal food-protein induced enterocolitis", "N-FPIES"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
2 / 128 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT03029091May 23, 201720/1/2017An Open-Label Trial of Losartan Potassium in Participants With Eosinophilic Esophagitis (EoE)A Preliminary Open-Label Trial of Losartan Potassium in Participants With Eosinophilic Esophagitis (EoE) With or Without a Connective Tissue DisorderEosinophilic EsophagitisDrug: Losartan PotassiumChildren's Hospital Medical Center, CincinnatiNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK);National Institute of Allergy and Infectious Diseases (NIAID);Office of Rare Diseases (ORD);National Center for Advancing Translational Science (NCATS)Completed5 Years25 YearsAll15Phase 2United States
2NCT01808196October 10, 201330/1/2013Testing Effectiveness of Losartan in Patients With EoE With or Without a CTDA Preliminary, Open-label Trial of Losartan Potassium in Participants With Eosinophilic Esophagitis (EoE) With or Without a Connective Tissue Disorder.Eosinophilic Esophagitis;Connective Tissue DisordersDrug: Losartan PotassiumChildren's Hospital Medical Center, CincinnatiNULLCompleted5 Years21 YearsAll6Phase 2United States

113. 筋ジストロフィー [臨床試験数:567,薬物数:442(DrugBank:93),標的遺伝子数:55,標的パスウェイ数:151
Searched query = "Muscular dystrophy", "Dystrophinopathies", "Myotilinopathy", "Laminopathy", "Caveolinopathy", "LGMD1C", "Desminopathy", "Sarcoglycanopathy", "α-dystroglycanopathy", "FCMD", "Walker-Warburg syndrome", "Muscle-eye-brain disease", "Myotonic dystrophy", "Integrin α7 deficient CMD", "Rigid spine syndrome"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
1 / 567 trial found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT01982695March 200929/10/2013Cardiomyopathy in DMD: Lisinopril vs. LosartanCompare Efficacy of the Angiotensin Converting Enzyme Inhibitor (ACEi) Lisinopril With Angiotensin II Receptor Antagonist Losartan (ARB) for the Cardiomyopathy of Duchenne Muscular DystrophyDuchenne Muscular Dystrophy (DMD);CardiomyopathyDrug: Losartan;Drug: LisinoprilNationwide Children's HospitalBoston Children’s Hospital;University of California, Davis;Unverisity of Kansas Medical Center;University of Minnesota - Clinical and Translational Science Institute;St. Louis Children's HospitalCompletedN/AN/AMale23N/AUnited States

164. 眼皮膚白皮症 [臨床試験数:15,薬物数:57(DrugBank:34),標的遺伝子数:34,標的パスウェイ数:136
Searched query = "Oculocutaneous albinism", "Hermansky-Pudlak syndrome", "Chediak-Higashi syndrome", "Griscelli syndrome"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
1 / 15 trial found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT00467831April 200728/4/2007Pilot Study of a Multi-Drug Regimen for Severe Pulmonary Fibrosis in Hermansky-Pudlak SyndromePilot Study of a Multi-Drug Regimen for Severe Pulmonary Fibrosis in Hermansky-Pudlak SyndromeHermansky-Pudlak Syndrome (HPS);Pulmonary Fibrosis;Oculocutaneous Albinism;Platelet Storage Pool Deficiency;Metabolic DiseaseDrug: Losartan;Drug: Zileuton;Drug: N-Acetylcysteine;Drug: Pravastatin;Drug: ErythromycinNational Human Genome Research Institute (NHGRI)NULLTerminated18 Years70 YearsAll3Phase 1/Phase 2United States

167. マルファン症候群 [臨床試験数:19,薬物数:38(DrugBank:10),標的遺伝子数:10,標的パスウェイ数:49
Searched query = "Marfan syndrome"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
12 / 19 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT00782327June 200929/10/2008Randomized, Double-blind Study for the Evaluation of the Effect of Losartan Versus Placebo on Aortic Root Dilatation in Patients With Marfan Syndrome Under Treatment With Beta-blockersRandomized, Double-blind Study for the Evaluation of the Effect of Losartan Versus Placebo on Aortic Root Dilatation in Patients With Marfan Syndrome Under Treatment With Beta-blockersMarfan SyndromeDrug: Losartan;Drug: PlaceboUniversity Hospital, GhentAgentschap voor Innovatie door Wetenschap en TechnologieRecruiting10 YearsN/ABoth174Phase 3Belgium
2EUCTR2007-005862-10-BE29/05/200907/01/2009Randomized, double-blind study for the evaluation of the effect of losartan versus placebo on aortic root dilatation in patients with Marfan syndrome under treatment with beta-blockers.Randomized, double-blind study for the evaluation of the effect of losartan versus placebo on aortic root dilatation in patients with Marfan syndrome under treatment with beta-blockers. Marfan syndrome
MedDRA version: 9.1Level: LLTClassification code 10026829Term: Marfan's syndrome
Trade Name: Cozaar
Product Name: Losartan
INN or Proposed INN: Losartan potassium
Trade Name: Coozar
Product Name: Losartan
INN or Proposed INN: Losartan potassium
Trade Name: Coozar
Product Name: Losartan
INN or Proposed INN: Losartan potassium
University Hospital GhentNULLNot RecruitingFemale: yes
Male: yes
Belgium
3EUCTR2008-001462-81-IT27/10/200817/03/2008Effects of Losartan versus Nebivolol versus the association of both on the progression of aortic root dilation in Marfan Syndrome (MFS) with FBN1 gene mutations - NDEffects of Losartan versus Nebivolol versus the association of both on the progression of aortic root dilation in Marfan Syndrome (MFS) with FBN1 gene mutations - ND Marfan Syndrome
MedDRA version: 9.1Level: LLTClassification code 10026829Term: Marfan's syndrome
Trade Name: LORTAAN*28CPR RIV DIV 50MG
INN or Proposed INN: Losartan
Trade Name: LOBIVON*28CPR 5MG
INN or Proposed INN: Nebivolol
OSPEDALE POLICLINICO S. MATTEONULLNot RecruitingFemale: yes
Male: yes
Phase 3Italy
4NCT01145612October 200815/6/2010Atenolol Versus Losartan in the Prevention of Progressive Dilation of the Aorta in Marfan SyndromeA Clinical Trial to Assess the Efficacy and Safety of Losartan Versus Atenolol in the Prevention of Progressive Dilation of the Aorta in Patients With Marfan Syndrome.Marfan SyndromeDrug: Losartan;Drug: AtenololForteza, Albert, M.D.Ministry of Health, SpainActive, not recruiting5 Years60 YearsBoth140Phase 3Spain
5NCT00763893September 200830/9/2008Study of the Efficacy of Losartan on Aortic Dilatation in Patients With Marfan SyndromeMulticenter, Randomised, Double Blind Study of the Efficacy of Losartan on Aortic Dilatation in Patients With Marfan SyndromeMarfan SyndromeDrug: placebo;Drug: LosartanAssistance Publique - Hôpitaux de ParisNULLTerminated10 YearsN/ABoth303Phase 3France
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
6NCT00683124July 200821/5/2008Nebivolol Versus Losartan Versus Nebivolol+Losartan Against Aortic Root Dilation in Genotyped Marfan PatientsEffects of Losartan vs. Nebivolol vs. the Association of Both on the Progression of Aortic Root Dilation in Marfan Syndrome (MFS) With FBN1 Gene Mutations.Marfan SyndromeDrug: Losartan and nebivolol;Drug: Losartan;Drug: NebivololIRCCS Policlinico S. MatteoMerck Sharp & Dohme Corp.;Menarini GroupRecruiting12 Months55 YearsBoth291Phase 3Italy
7EUCTR2007-001125-97-ES20/05/200803/12/2007Eficacia y Seguridad de Losartán vs Atenolol en la prevención de la dilatación progresiva de la aorta en la población de pacientes con Síndrome de Marfan (Losartan vs atenolol efficacy and security in aortic dilatation prevention in Marfan syndrome)Eficacia y Seguridad de Losartán vs Atenolol en la prevención de la dilatación progresiva de la aorta en la población de pacientes con Síndrome de Marfan (Losartan vs atenolol efficacy and security in aortic dilatation prevention in Marfan syndrome) The aortic dilatation in Marfan syndrome with two different treatments: losartan vs atenolol
MedDRA version: 9.1Level: LLTClassification code 10026829Term: Marfan's syndrome
Trade Name: cozaar 50
INN or Proposed INN: LOSARTAN POTASSIUM
Trade Name: blokium 50
INN or Proposed INN: ATENOLOL
Trade Name: COZAAR INICIO 12,5 mg comprimidos recubiertos con pelicula
INN or Proposed INN: LOSARTAN POTASSIUM
Trade Name: BLOKIUM 50 mg comprimidos
INN or Proposed INN: ATENOLOL
alberto fortezaNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
Spain
8NCT00593710January 20083/1/2008Losartan Versus Atenolol for the Treatment of Marfan SyndromeA Randomized Double-blind Study Assessing the Effects of Losartan Versus Atenolol on Pulse Wave Velocity and the Biophysical Properties of the Aorta in Patients With Marfan SyndromeMarfan SyndromeDrug: Losartan;Drug: AtenololUniversity of British ColumbiaHeart and Stroke Foundation of CanadaCompleted12 Years25 YearsBoth17Phase 2Canada
9NCT00723801October 200725/7/2008Effects of Losartan Versus Atenolol on Aortic and Cardiac Muscle Stiffness in Adults With Marfan SyndromeEffects of Losartan vs Atenolol on Aortic Stiffness and Diastolic Function in Adults With Marfan SyndromeMarfan SyndromeDrug: Atenolol;Drug: LosartanBrigham and Women's HospitalBoston Children’s HospitalCompleted25 YearsN/AAll40Phase 3United States
10NCT00651235February 20073/3/2008A Randomized, Open-label, LOSARTAN Therapy on the Progression of Aortic Root Dilation in Patients With Marfan SyndromeA Randomized, Open-label, Active Control Trial to Evaluate the Effect of LOSARTAN Therapy on the Progression of Aortic Root Dilation in Patients With Marfan SyndromeMarfan SyndromeDrug: Losartan and Atenolol or Propranolol;Drug: Atenolol or PropranololNational Taiwan University HospitalNULLRecruiting1 YearN/ABoth44Phase 2Taiwan
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
11NCT00429364January 200729/1/2007Comparison of Two Medications Aimed at Slowing Aortic Root Enlargement in Individuals With Marfan Syndrome--Pediatric Heart NetworkTrial of Beta Blocker Therapy (Atenolol) Versus Angiotensin II Receptor Blocker Therapy (Losartan) in Individuals With Marfan Syndrome (A Trial Conducted by the Pediatric Heart Network)Marfan SyndromeDrug: Losartan Potassium;Drug: AtenololNew England Research InstitutesNational Heart, Lung, and Blood Institute (NHLBI);FDA Office of Orphan Products Development;National Marfan FoundationCompleted6 Months25 YearsAll608Phase 3United States;Belgium;Canada
12EUCTR2006-003991-37-BE13/12/200606/12/2006Trial of beta blocker therapy (atenolol) vs. angiotensin II receptor blocker therapy (losartan) in individuals with Marfan syndrome - Marfan TrialTrial of beta blocker therapy (atenolol) vs. angiotensin II receptor blocker therapy (losartan) in individuals with Marfan syndrome - Marfan Trial Marfan syndrome
MedDRA version: 8.1Level: LLTClassification code 10026829Term: Marfan's syndrome
Product Name: losartan
INN or Proposed INN: Losartan potassium
Product Name: losartan
INN or Proposed INN: Losartan potassium
Product Name: losartan
INN or Proposed INN: Losartan potassium
Product Name: Atenolol
INN or Proposed INN: Atenolol
Product Name: Atenolol
INN or Proposed INN: Atenolol
Product Name: Atenolol
INN or Proposed INN: Atenolol
University Hospital GentNULLNot RecruitingFemale: yes
Male: yes
600Belgium

179. ウィリアムズ症候群 [臨床試験数:4,薬物数:13(DrugBank:7),標的遺伝子数:8,標的パスウェイ数:32
Searched query = "Williams syndrome"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
1 / 4 trial found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2007-006059-37-ES27/05/200919/08/2008ENSAYO CLÍNICO PILOTO, ALEATORIZADO, CONTROLADO, PARALELO, DOBLE-CIEGO, PARA EVALUAR LA EFICACIA Y SEGURIDAD DE LOSARTÁN EN LA REDUCCIÓN DEL ESTRÉS OXIDATIVO Y LA DISMINUCIÓN DE LA TENSIÓN ARTERIAL (TA) EN PACIENTES CON SÍNDROME DE WILLIAMS (SW) Y DOS O MÁS COPIAS DEL GEN NCF1. - LOSARTANWILLIAMSENSAYO CLÍNICO PILOTO, ALEATORIZADO, CONTROLADO, PARALELO, DOBLE-CIEGO, PARA EVALUAR LA EFICACIA Y SEGURIDAD DE LOSARTÁN EN LA REDUCCIÓN DEL ESTRÉS OXIDATIVO Y LA DISMINUCIÓN DE LA TENSIÓN ARTERIAL (TA) EN PACIENTES CON SÍNDROME DE WILLIAMS (SW) Y DOS O MÁS COPIAS DEL GEN NCF1. - LOSARTANWILLIAMS Pacientes con síndrome de Williams con evidencia molecular de microdeleción en 7q11.2. Edad: Niños de más de 5 años y adultos Sexo: ambos sexos estarán representados lo más paritariemente posible Variante molecular de la deleción que confirme la presencia de 2 o más copias del gen NCF1.
MedDRA version: 9.1Level: LLTClassification code 10049644Term: Williams syndrome
Trade Name: COZAAR 50 mg comprimidos recubierto con pelicula
INN or Proposed INN: LOSARTAN POTASICO
Other descriptive name: LOSARTAN POTASSIUM
Programa de Medicina Molecular y Genética, Hospital Vall d´HebronNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
60Spain

215. ファロー四徴症 [臨床試験数:19,薬物数:35(DrugBank:16),標的遺伝子数:16,標的パスウェイ数:47
Searched query = "Tetralogy of Fallot", "Fallot tetralogy"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
2 / 19 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2013-002091-41-NL09/10/201405/11/2013Research into the effect of the drug losartan in adult patients with a reduced function of the right cardiac chamber and a cardiac birth defectRight vEntricular Dysfunction in tEtralogy of Fallot: INhibition of the rEnin-angiotensin-aldosterone system - Redefine trial To study the effect of losartan in adult patients with Tetralogy of Fallot and right ventricular dysfunction, defined as right ventricular ejection fraction <50%. Without severe valvular lesions.;Therapeutic area: Diseases [C] - Cardiovascular Diseases [C14]Trade Name: Losartan
Product Name: Losartan
INN or Proposed INN: Losartan Potassium
Other descriptive name: LOSARTAN POTASSIUM
Academisch medisch centrumNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
Netherlands
2NCT02010905December 20136/12/2013Right Ventricular Dysfunction in Tetralogy of Fallot: Inhibition of the Renin-angiotensin-aldosterone SystemRight Ventricular Dysfunction in Tetralogy of Fallot: Inhibition of the Renin-angiotensin-aldosterone SystemTetralogy of Fallot;Heart Defects, Congenital;Ventricular Dysfunction, RightDrug: Losartan;Drug: PlaceboAcademisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)The Interuniversity Cardiology Institute of the NetherlandsRecruiting18 Years80 YearsBoth120Phase 2Netherlands

222. 一次性ネフローゼ症候群 [臨床試験数:234,薬物数:241(DrugBank:78),標的遺伝子数:59,標的パスウェイ数:185
Searched query = "Primary nephrotic syndrome", "Minimal change nephrotic syndrome", "MCNS", "Membranous nephropathy", "Focal segmental glomerulosclerosis", "FSGS", "Membranoproliferative glomerulonephritis", "MPGN"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
3 / 234 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1ChiCTR-TRC-140050642014-09-012014-08-06A prospective study on the safety and efficacy of treatment with Qiluxiaobai formula for CKD 2-3 stageInvestigation on the Mechanisms Of Invigorating Spleen Dissipating Dampness Principle On The Treatment Of Podocyte Injury In Focal Segmental Glomerulosclerosis chronic kidney disease1:basic treatment and losartan K 50mg qd;2:basic treatment and QLXB formula 200ml qd ;Shanghai University of T.C.MNULLRecruiting1860Both1:50;2:50;China
2NCT01845688November 201129/4/2013Clinical Study of QingReMoShen Granule to Treat Idiopathic Membranous NephropathyEfficacy and Safety Evaluation of QingReMoShen Granule in the Treatment of Idiopathic Membranous Nephropathy : A Randomized Double-Blind Controlled Clinical StudyIdiopathic Membranous NephropathyDrug: Losartan Tablets & QingReMoShen Granule;Drug: Losartan Tablets & Placebo GranulewanglinNULLActive, not recruiting18 Years70 YearsBoth72N/AChina
3NCT00814255December 200822/12/2008Novel Therapies for Resistant FSGS (FONTII): Phase II Clinical TrialNovel Therapies for Resistant Focal Segmental GlomerulosclerosisFocal Segmental GlomerulosclerosisDrug: Adalimumab;Drug: Lisinopril, losartan, and atorvastatin;Drug: galactoseNew York University School of MedicineUniversity of Michigan;The Cleveland Clinic;National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Completed1 Year65 YearsAll32Phase 2United States;Canada

299. 嚢胞性線維症 [臨床試験数:1,592,薬物数:1,539(DrugBank:255),標的遺伝子数:81,標的パスウェイ数:162
Searched query = "Cystic fibrosis"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
2 / 1,592 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT03435939February 1, 20215/2/2018Effect of Losartan in Cystic Fibrosis (CF)-NIH Grant #133240Anti-Inflammatory Therapy to Augment CFTR Rescue in CF PatientsCystic FibrosisDrug: LosartanUniversity of Kansas Medical CenterNULLNot yet recruiting18 YearsN/AAll16Early Phase 1United States
2NCT03206788November 11, 201729/6/2017Losartan and Inflammation in Cystic FibrosisLosartan as Anti-inflammatory Therapy to Augment F508del Cystic Fibrosis Transmembrane (CFTR) RecoveryCystic FibrosisDrug: Losartan;Drug: placeboUniversity of MiamiUniversity of Alabama at Birmingham;Children's Hospital Medical Center, Cincinnati;University of Kansas Medical Center;Cystic Fibrosis FoundationTerminated12 YearsN/AAll7Phase 2United States